JP2016503397A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503397A5
JP2016503397A5 JP2015539720A JP2015539720A JP2016503397A5 JP 2016503397 A5 JP2016503397 A5 JP 2016503397A5 JP 2015539720 A JP2015539720 A JP 2015539720A JP 2015539720 A JP2015539720 A JP 2015539720A JP 2016503397 A5 JP2016503397 A5 JP 2016503397A5
Authority
JP
Japan
Prior art keywords
subject
agent
composition
heart failure
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015539720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503397A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/066228 external-priority patent/WO2014066419A2/en
Publication of JP2016503397A publication Critical patent/JP2016503397A/ja
Publication of JP2016503397A5 publication Critical patent/JP2016503397A5/ja
Pending legal-status Critical Current

Links

JP2015539720A 2012-10-22 2013-10-22 心不全関連リスクおよびそれらと関連する因子を減少させる方法 Pending JP2016503397A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261716867P 2012-10-22 2012-10-22
US61/716,867 2012-10-22
US201361822752P 2013-05-13 2013-05-13
US61/822,752 2013-05-13
US201361839750P 2013-06-26 2013-06-26
US201361839743P 2013-06-26 2013-06-26
US61/839,750 2013-06-26
US61/839,743 2013-06-26
PCT/US2013/066228 WO2014066419A2 (en) 2012-10-22 2013-10-22 Methods for reducing risks associated with heart failure and factors associated therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018018942A Division JP2018109012A (ja) 2012-10-22 2018-02-06 心不全関連リスクおよびそれらと関連する因子を減少させる方法

Publications (2)

Publication Number Publication Date
JP2016503397A JP2016503397A (ja) 2016-02-04
JP2016503397A5 true JP2016503397A5 (enExample) 2016-12-08

Family

ID=50545459

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015539720A Pending JP2016503397A (ja) 2012-10-22 2013-10-22 心不全関連リスクおよびそれらと関連する因子を減少させる方法
JP2018018942A Pending JP2018109012A (ja) 2012-10-22 2018-02-06 心不全関連リスクおよびそれらと関連する因子を減少させる方法
JP2019104270A Pending JP2019194193A (ja) 2012-10-22 2019-06-04 心不全関連リスクおよびそれらと関連する因子を減少させる方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018018942A Pending JP2018109012A (ja) 2012-10-22 2018-02-06 心不全関連リスクおよびそれらと関連する因子を減少させる方法
JP2019104270A Pending JP2019194193A (ja) 2012-10-22 2019-06-04 心不全関連リスクおよびそれらと関連する因子を減少させる方法

Country Status (13)

Country Link
US (4) US20150246092A1 (enExample)
EP (5) EP4711005A3 (enExample)
JP (3) JP2016503397A (enExample)
KR (1) KR20160009008A (enExample)
CN (2) CN105050613A (enExample)
AU (2) AU2013334788A1 (enExample)
BR (1) BR112015009072A2 (enExample)
CA (1) CA2889155A1 (enExample)
ES (1) ES3058737T3 (enExample)
MX (1) MX2015005102A (enExample)
NI (1) NI201500057A (enExample)
PE (1) PE20151434A1 (enExample)
WO (1) WO2014066419A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2750258T3 (es) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Métodos y composiciones para la prevención o tratamiento del síndrome de Barth
CN117752766A (zh) 2013-03-01 2024-03-26 康德生物医疗有限公司 治疗线粒体疾病的方法
WO2014209905A2 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
CN109414472A (zh) * 2016-06-24 2019-03-01 南加利福尼亚大学 Mentsh类似物作为用于糖尿病、肥胖及其相关疾病和并发症的治疗剂
TWI716668B (zh) * 2017-02-01 2021-01-21 耶魯大學 心臟衰竭及心腎症候群之精準治療
MX2020006882A (es) 2018-01-05 2020-09-07 Novo Nordisk As Metodos para tratar inflamacion mediada por interleucina-6 sin inmunosupresion.
KR102546547B1 (ko) 2018-01-11 2023-06-22 삼성전자주식회사 보행 보조 방법 및 장치
KR20220052561A (ko) 2020-10-21 2022-04-28 장영진 어류 가공물 및/또는 콩 가공물을 유효성분으로 포함하는 심부전의 예방 또는 치료용 약학 조성물
CN120329388B (zh) * 2025-04-30 2025-09-26 中日友好医院(中日友好临床医学研究所) 一种双靶点多肽及其在心衰治疗中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
PL218992B1 (pl) * 2002-07-19 2015-02-27 Abbott Biotech Ltd Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
ES2436011T3 (es) * 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
EP1890154B1 (en) * 2006-08-16 2012-07-04 F. Hoffmann-La Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
EP1890153A1 (en) * 2006-08-16 2008-02-20 F. Hoffman-la Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
US20080318909A1 (en) * 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
DK2262520T3 (en) * 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
DK2464371T3 (en) * 2009-08-12 2016-06-27 Univ Cornell Methods for preventing or treating metabolic syndrome
EP2764871A1 (en) * 2009-10-05 2014-08-13 Cornell University Methods for the prevention or treatment of heart failure
EP2504032A4 (en) * 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
US20130190244A1 (en) * 2009-12-31 2013-07-25 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
WO2011082324A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP3511012A1 (en) * 2010-02-26 2019-07-17 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP2547352A4 (en) * 2010-03-15 2013-10-09 Stealth Peptides Int Inc COMBINATION THERAPIES USING CYCLOSPORINE AND AROMATIC CATIONIC PEPTIDES
JP2015524439A (ja) * 2012-08-02 2015-08-24 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
EP3459598A1 (en) * 2012-12-06 2019-03-27 Stealth Peptides International, Inc. Combinations of peptide therapeutics and methods for using same
WO2014210062A1 (en) * 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods for the regulation of matrix metalloproteinase expression
WO2014209905A2 (en) * 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions

Similar Documents

Publication Publication Date Title
Angeli et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide
Selman et al. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches
Dagher et al. The hepatorenal syndrome
Browne et al. Pathophysiology of pulmonary complications of acute pancreatitis
Sezai et al. Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery: a randomized controlled study
Ahmadi et al. Thyroid gland dysfunction and its effect on the cardiovascular system: a comprehensive review of the literature
TWI505827B (zh) 治療高尿酸血症及與高尿酸血症有關之新陳代謝疾病之方法及組合物
Ergul Endothelin‐1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents
JP2016522196A5 (enExample)
JP2022137224A (ja) 低血圧治療のための単独または併用使用されるアンギオテンシンｉｉ
JP2016511259A5 (enExample)
Kitakaze et al. levation of Plasma Adenosine Levels May Attenuate the Severity of Chronic Heart Failure
JP2006502152A (ja) 線維性疾患治療用の併用療法
Medarov et al. Clinical aspects of portopulmonary hypertension
Møller et al. Pathogenesis and pathophysiology of hepatorenal syndrome–is there scope for prevention?
Shibahara et al. Cardiorenal protective effect of the oral uremic toxin absorbent AST-120 in chronic heart disease patients with moderate CKD
Xu et al. Protective role of AT2 and B1 receptors in kinin B2-receptor-knockout mice with myocardial infarction
van der Jagt et al. Beta-blockers in intensive care medicine: potential benefit in acute brain injury and acute respiratory distress syndrome
Ye et al. Inhibition of the P2X7 receptor prevents atrial proarrhythmic remodeling in experimental post-operative atrial fibrillation
McBride et al. Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management
Rosseel et al. Postcardiac surgery low cardiac output syndrome: dopexamine or dopamine?
WO2023183339A1 (en) Selective vasopressin receptor agonist for end-stage liver disease
Morganti et al. Aliskiren: the first direct renin inhibitor available for clinical use
JP2021530517A5 (enExample)
Kupferschmid et al. Amiodarone-induced complications after cardiac operation for obstructive hypertrophic cardiomyopathy